Scientists in the Departments of Radiation Oncology and Medicine at the University of Washington (UW) and Fred Hutchinson Cancer Center (Fred Hutch) are directly targeting cancerous cells traveling through patients’ bloodstreams with diseases such as leukemia and lymphoma using an intravenous injection of the radioactive isotope astatine-211 (At-211). The work, its challenges, and its promise were described in a recent news release from the National Isotope Development Center (NIDC), which is managed by the Department of Energy’s Isotope Program.

Last April, Entergy had to close its Indian Point nuclear plant. That’s despite the plant’s being recognized as one of the best-run U.S. nuclear plants. That’s also despite its 20-year license extension process having been nearly completed, with full support from the Nuclear Regulatory Commission.

This closure was due in large part to opposition by antinuclear environmental groups. These groups also mobilized existing negative public opinion on nuclear energy to get politicians to oppose the plant’s license extension. Another factor is unfair market conditions. Nuclear energy doesn’t get due government support—unlike solar, wind, and hydro—despite delivering clean, zero-emissions energy.